NCT04803123View on ClinicalTrials.gov

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

April 3, 2023

Study Completion Date

April 26, 2023

Conditions
Leukemia, Acute Lymphocytic
Interventions
DRUG

Copanlisib

Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.

Trial Locations (1)

27710

Duke Cancer Center, Durham

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Dorothy Sipkins, MD, PhD

OTHER